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Increased attention has been drawn to the important role played by regulatory T-cells (Treg) in immune
homoeostasis. However, the small numbers of Tregs make them elusive to study. We investigated the
cryostability of Tregs and whether they can be expanded from cryopreserved peripheral blood
mononuclear cells (PBMCs). Further, to elucidate if there is a difference in ex-vivo frequency or
in vitro expansion of Tregs among T1D children (n¼9), high-risk (n¼7) and healthy (n¼10) individuals,
Tregs deﬁned as CD4þCD25þCD127lo/ were isolated from cryopreserved PBMCs.
Cryopreserved PBMCs maintained a stable expression of Treg-markers. Tregs were efﬁciently
expanded in vitro from all donors and Tregs from T1D children acquired higher FOXP3 expression
compared to healthy subjects. T1D children had a signiﬁcantly lower percentage of Tregs among CD4þ
T-cells and also lower Treg to CD4þCD25 cell ratios compared to healthy individuals.
& 2011 Elsevier B.V. Open access under CC BY-NC-ND license. 1. Introduction
To maintain self-tolerance along with a sufﬁcient protection
against the many threats encountered in everyday life, the
immune system needs to keep a plastic balance between up-
and down-regulating mechanisms. Loss of this plasticity may
result in autoimmunity. Type 1 Diabetes (T1D) is connected to an
autoimmune process towards the insulin producing pancreatic
b-cells and is the most common chronic disease in children in
developed countries. T1D is associated with a signiﬁcant burden
of daily insulin injections, regular and controlled meals and close
monitoring of blood glucose values. Despite great efforts to keep
blood glucose in check, children with T1D are often affected by
acute complications (e.g. hypoglycaemia) and chronic micro- and
macro-vascular complications.
The autoimmune attack on the beta-cells is considered to be of
a T-helper (Th) 1-like effector origin, i.e. connected to cell-
mediated immunity and an interferon-g (IFN-g) and tumour
necrosis factor (TNF) rich milieu [1–3]. It is also associated with
the presence of islet cell autoantibodies towards glutamic acid
decarboxylase (GAD65), insulin, the islet tyrosine phosphatase
IA-2 [4] and zinc transporter 8 (ZnT8) [5]. We have previouslyrch, Division of Paediatrics,
-581 85 Linko¨ping, Sweden.
Y-NC-ND license. reported a Th1-like dominated proﬁle in high-risk ﬁrst-degree
relatives of T1D children, characterized by high production of
IFN-g [6]. We and others have, however, observed that this strong
bias towards Th1 immunity vanishes close to T1D onset and
remains suppressed in newly diagnosed patients, as documented
by reduced IFN-g mRNA expression and secretion both in unsti-
mulated conditions and after in vitro mitogen stimulation [6–8].
Establishment of T-cell tolerance takes place both centrally in
the thymus and through various mechanisms in the periphery [9].
The strongly suppressive regulatory T-cells (Tregs) are bridging
central and peripheral tolerance mechanisms through thymic
derived and peripherally induced subsets. A common description
of the Treg phenotype is the concurrent expression of CD4 and
high constitutive expression of the alpha chain of the IL-2
receptor (CD25) [10]. To further identify a regulatory population
devoid of activated effector T-cells, a number of markers have
been described, most notably absent or low expression of the IL-7
receptor CD127 [11,12]. However, pinpointing a pure Treg popu-
lation is a complex task in humans due to the lack of a speciﬁc
and unique Treg marker together with the heterogeneity of this
population. The transcription factor forkhead box P3 (FOXP3), found
to be expressed in CD4þCD25þ Tregs [13], was also found to be
transiently expressed in activated effector T-cells [14,15]. FOXP3þ
Tregs also constitutively express the inhibitory molecule CTLA-4 [16],
while other T-cell subsets express this protein only transiently upon
activation. In mouse models completely deprived of Tregs, a variety
of autoimmune diseases develop and, likewise, FOXP3 mutations in
man cause immune dysregulation, polyendocrinopathy, enteropathy,
A. Ryde´n, M. Faresjo¨ / Results in Immunology 1 (2011) 36–44 37X-linked (IPEX) syndrome [17,18]. Furthermore, a variety of diseases
and autoimmune states have been associated with impaired Treg
function [10,17–20], while re-introduction of CD4þCD25hi Treg cells
into non-obese diabetic (NOD) mice has shown to prevent the
development of T1D and to inhibit the production of IFN-g [21].
In the research ﬁeld of T1D, where study subjects are often
children, blood volumes available for T-cell studies are limited
and samples given must be carefully handled and used to its full
extent. Cryopreservation of peripheral blood mononuclear cells
(PBMC) in liquid nitrogen allows for batch analysis of samples,
but the number of Tregs that can be recovered is limited (5–7%
of CD4þ T-cells) [22]. In vitro expansion of these cells would
therefore be most valuable for biological investigations, and,
possibly, for adoptive cell therapies.
In the present study, we sought to investigate the cryostability of
Treg associated markers and further to sort and expand Tregs from
cryopreserved PBMC of T1D, high-risk and healthy individuals. The
aim was to efﬁciently expand Tregs and to detect any difference in
T-cell number and composition among the studied subjects.2. Materials and methods
2.1. Subjects
For the pre-study, sodium-heparinized venous blood samples
were obtained from 16 healthy adults (8 females and 8 males,
median age 26.5 years, range 23.5–31).
For isolation and expansion, sodium-heparinized venous blood
samples were obtained from 9 T1D children (4 females and 5 males,
median age 10 years, range 4–14) between 20 days and 10 months
after diagnosis (median disease duration 3 months). These patients
were compared with 7 high-risk individuals (3 females and 4 males,
median age 18 years, range 11–48) who had previously participated
in the European Nicotinamide Diabetes Intervention Trial (ENDIT)
[23] and who had up to a 40% risk of developing T1Dwithin ﬁve years
(Z20 ICA IJDF units), and with 10 healthy subjects (5 females and
5 males, median age 23.5 years, range 8–31) without a family history
of T1D (Table 1). Blood samples from children with T1D were taken
during visits to the Linko¨ping diabetes clinic, and blood samples from
healthy individuals were taken at school or at the work place, when
possible during the morning hours to avoid time-of-day differences.
Blood samples from high-risk individuals were transported to Linko¨p-
ing within 24 h of blood sampling. None of the study subjects showed
any signs of cold or other infections, at the time of sampling.
2.2. PBMC isolation, cryopreservation and thawing
PBMCs were isolated by Ficoll Paque density gradient centri-
fugation (Amersham/Pharmacia), as described previously [6]. ForTable 1
Study subjects.
Healthy Age Gender T1D Duration Age Gender High-
HC1 9 Female T1D1 3 months 4 Female HR1
HC2 13 Male T1D2 6 months 11 Female HR2
HC3 8 Male T1D3 9 months 10 Male HR3
HC4 15 Male T1D4 5 months 4 Male HR4
HC5 27 Female T1D5 10 months 14 Male HR5
HC6 23 Female T1D6 1 month 11 Male HR6
HC7 25 Female T1D7 3 months 13 Female HR7
HC8 25 Male T1D8 20 days 9 Female
HC9 31 Female T1D9 1 month 5 Male
HC10 24 Male
Composition of study population (healthy (HC), Type 1 diabetes (T1D) and high-risk (H
and treatment with nicotinamide versus placebo, and development of T1D in high-riskcryopreservation, freezing medium (40% RPMI 1640 (Invitrogen),
10% DMSO (dimethyl sulphoxide, Sigma) and 50% foetal calf
serum (FCS) (Gibco/Invitrogen)) were added dropwise to PBMC
resulting in a cell suspension of 5106 cells/ml, divided into
aliquots of 1 ml in cryotubes and freezed at 70 1C in a pre-
cooled (4 1C) freezing container (Mr Frosty NALGENE Labware),
allowing a lowering of the temperature of 1 1C/min. The following
day the cryotubes were transferred into liquid nitrogen for
storage until further use.
Cryopreserved PBMCs were thawed directly under gentle
agitation in a 37 1C water bath and immediately washed in RPMI
1640 supplemented with 10% human serum (HS) before staining
and sorting.2.3. Antibodies
For staining and sorting, ﬂuorescein isothiocyanate (FITC)-con-
jugated anti-CD127, allophycocyanin (APC)-conjugated anti-CD25
(both from eBioscience) and paciﬁc blue (PB)-conjugated anti-CD4
(clone OKT4, produced in-house) and Alexa 700-conjugated anti-
FOXP3 (eBioscience) mAbs were used. For comparison of marker
expression in the pre-study, FITC-conjugated anti-FOXP3 (Nordic
BioSite), APC-conjugated anti-CD25 and PerCP-conjugated anti-CD4
(Becton Dickinson (BD) Biosciences) mAbs were used. Cells were
stained for 30 min at 4 1C and washed in phosphate buffered saline
(PBS) supplemented with 2% HS. For intracellular staining, Alexa
700-conjugated anti-FOXP3 was used following ﬁxation and per-
meabilization with appropriate buffers (Miltenyi).2.4. Flow cytometry acquisition and sorting
PBMCs were analysed and sorted using a FACSAria (Becton
Dickinson) equipped with 488, 633 and 407 nm lasers. Lympho-
cytes were gated based on forward (FSC) and side scatter (SSC).
For examination of Treg-marker expression before and after
cryopreservation, in the pre-study, CD25hi cells were gated as
CD4þ T lymphocyte subsets expressing higher levels of CD25
than the discrete population of CD4 cells expressing CD25.
FOXP3 expression was then analysed in this gate. Also for sorting,
CD4 expressing lymphocytes were gated to further obtain
a dot plot of CD25 and CD127 ﬂuorescence. Tregs were gated
as CD4þCD25þCD127lo/ and compared to CD4þCD25 and
CD4þCD25þCD127þ subpopulations (Fig. 1). The concurrent
expressions of CD25 and FOXP3, following expansion of
CD4þCD25þCD127lo/ and CD4þCD25 cultures, were analysed
and compared to each other, as seen in Fig. 5a–c. The cut-offs for
the gates were set after the ﬂuorescence of a biologically FOXP3
negative and CD25 negative population. Data was analysed using
the FlowJo software (Tree Star) and expressed as meanrisk Age Gender Treatment Developed T1D
17 Female Placebo Yes 8.5 years post-sampling
41 Female Nicotinamide Yes 10 years post-sampling
12 Male Nicotinamide Yes 4 years post-sampling
42 Female Placebo Yes 1.5 years post-sampling
18 Male Placebo No
11 Male Placebo No
48 Male Nicotinamide No
R)), regarding age (years), gender (female/male), disease duration (days/months)
individuals after inclusion in the study cohort (years).
Fig. 1. Gating strategy for sorting of CD4þCD25þCD127lo/ Treg. Lymphocyte population was gated based on forward and side scatter and from this gate CD4þ cells were
isolated and further gated for expression or no expression of CD25 and CD127.
Table 2
Expansion of CD4þCD25þCD127lo/ .
Cell number Vessel Media volume Dyanabeads (ll) rhIL-2
(U/ml)
40,000 96 well 125 ml2 1 300
100,000–150,000 48 well 500 ml2 2.5–3.75 300
200,000–300,000 24 well 1 ml2 5–7.5 300
400,000 12 well 1.5 ml2 10 300
800,000 6 well 2 ml2 20 300
1,200,000 Vertical T25 3 ml2 30 300
2,400,000 Horizontal T25 5 ml2 60 300
7,500,000 T75 15 ml2 187.5 300
17,000,000 T175 35 ml2 425 300
Media: AIM-V medium containing 10% HS and amphotericin B
Dynabeadss Human Treg Expander
Description of the experimental set-up for expansion of CD4þCD25þCD127lo/ .
2¼the same volume were added at day 0 and again at day 2.
For culture split or restimulation, the double volume was added.
Table 3
Expansion of CD4þCD25 .
Cell number Vessel Media volume CD28
(lg/ml)
rhIL-2
(U/ml)
o500,000 96 well 125 ml2 1 30
500,000 48 well 500 ml2 1 30
1106 24 well 1 ml2 1 30
When cells exceed 2.5106 or medium turns yellow, split back to 1106/24
well
50106 T175 40 ml2 1 30
Media: AIM-V medium containing 10% HS and amphotericin B
Vessels precoated with antiCD-3 (OKT3 10 mg/ml)
Description of the experimental set-up for expansion of CD4þCD25 cells.
2¼the same volume was added at day 0 and again at day 2.
For culture split or restimulation, the double volume was added.
A. Ryde´n, M. Faresjo¨ / Results in Immunology 1 (2011) 36–4438ﬂuorescence intensity (MFI; geometrical and standard mean) and
percentages of cells expressing each marker.
2.5. In vitro expansion
Tregs were expanded according to a protocol adapted from
Putnam et al. [24]. Brieﬂy, on day 0 sorted cells were resuspended
in AIM-V medium (Gibco/Invitrogen) containing 10% HS and
amphotericin B and plated according to Table 2. Dynabeadss
Human Treg Expander anti-CD3/anti-CD28 coated microbeads
(Invitrogen; catalogue number 111.61D) were added at a 1:1
bead to cell ratio. When Treg numbers were lower than 40.000,
96-well ﬂat-bottomed plates were used.
The cell culture volume was doubled at day 2 and IL-2
(Proleukin, Chiron Therapeutics) added at a ﬁnal concentration
of 300 U/ml. On days 5 and 7, cells were counted, washed in AIM-
V and resuspended as above, adding fresh IL-2. Restimulation
with anti-CD3/anti-CD28 coated microbeads, was performed on
day 9, as described for day 0. Cells were counted again on day 11
and 13, washed, resuspended according to Table 2, and supple-
mented with fresh IL-2. Cultures were terminated on day 15 and
cells stained for FOXP3 analysis.
CD4þCD25 cells were expanded according to a scheme
similar to Tregs, with the following alterations. As anti-CD3/
anti-CD28 coated microbeads caused overstimulation andactivation-induced apoptosis, CD4þCD25 cells were expanded
using anti-CD3 (OKT3, 10 mg/ml) coated culturing vessels
(Table 3) and soluble anti-CD28 (1 mg/ml). IL-2 addition was
added at a concentration of 30 U/ml.
2.6. Statistics
As expression of Treg-markers was not normally distributed,
two-group comparisons were performed with the Mann–Whitney
U-test, while three or more groups were compared using the
Kruskal–Wallis test for unpaired observations. For pair-wise
comparisons, Wilcoxon signed rank test was used. A probability
level o0.05 was considered statistically signiﬁcant. Calculations
were performed using the statistical package GraphPad Prism
version 5.01 for Windows (GraphPad Software, Inc.).
2.7. Ethics
The study was approved by the Research Ethics Committee of
the Faculty of Health Sciences, Linko¨ping University. Informed
consent was obtained from all volunteers and/or their parents.3. Results
3.1. Marker expression following cryopreservation
Before sorting of Tregs, a small pre-study of healthy volunteering
adults was performed assessing the stability of Treg-markers through
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thawing of PBMC to yield any differences in the percentage of FOXP3
expressing cells or the FOXP3 MFI, in the CD4þCD25hi cell popula-
tion (Fig. 2a,b). Neither the MFI of CD25 in the CD4þCD25hi Treg
population displayed any differences after cryopreservation (Fig. 2c).
These data encouraged our belief in the feasibility of the use of
cryopreserved PBMCs for this type of applications.
In the pre-study, we examined the eventual interference of
cryopreservation on Tregs based on FOXP3 expression in the strict
CD4þCD25hi gate. This same strategy was not optimal for sorting
due to the demand for membrane permeabilization and the limited
sample sizes from the study cohort and the very limited cell
numbers obtainable in this gate. Therefore, based on previous
studies showing the IL-7 receptor CD127 to be strongly negatively
correlated to FOXP3 expression, we choose to deﬁne Tregs as
CD4þCD25þCD127lo/ cells. Before settling, we compared the
appearance of the chosen sorting gate and the percentages and
MFIs of these markers (CD4, CD25 and CD127) and FOXP3 expres-
sion, before and after cryopreservation, in two healthy adults. This
experiment showed no contradiction between fresh and cryopre-
served samples, conﬁrming our strategy (data not shown).ns
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Following sorting of CD4þCD25þCD127lo/ Tregs and
CD4þCD25 , cells were cultured for expansion according to a
ﬁfteen day long protocol (Tables 2 and 3). All individuals, indepen-
dent of study group, were able to achieve a great increase (mean
fold change 144, median fold change 104) in CD4þCD25þCD127lo/
numbers (Fig. 3a), even starting with as few as four thousands
sorted CD4þCD25þCD127lo/ T-cells. CD4þCD25 however, were
harder to expand, never reaching the same magnitude in fold
increase as did the expansion of CD4þCD25þCD127lo/ T-cells
(Fig. 3b). No differences in fold increase of CD4þCD25þCD127lo/
or CD4þCD25 were seen between the study groups (data not
shown) even if CD4þCD25þCD127lo/ T-cells of healthy individuals
seem to reach a higher fold increase (3c).
3.3. Composition of CD25þ and/or CD127þ expressing CD4þ cells
Analysing the composition of CD4þ cells in the three study
groups, differences became apparent. T1D children showed a
lower percentage of CD4þCD25þCD127lo/ cells in the CD4þ55
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(po0.05, Fig. 4a). Lower CD4þCD25þCD127lo/ cell counts in
T1D were also true comparing CD4þCD25þCD127lo/ cells to
CD4þCD25 (po0.01, Fig. 4b). Further, T1D was associated with
signiﬁcantly higher percentages of CD4þCD25 , compared to
both healthy (po0.0001) and high-risk (po0.01) individuals
(Fig. 4c). In line with these results, T1D was associated with a
lower percentage of the total CD4þCD25þ cell count, compared
to the one seen in healthy individuals (po0.05, Fig. 4d) and also
tended to compared to in individuals at high risk of developing
the disease (po0.1, Fig. 4d). Moreover, T1D was associated with
lower fractions of CD25þCD127þ cells in the CD4þ population,
when compared to healthy individuals (po0.05, Fig. 4e).
3.4. Post-expansion expression of FOXP3
After ﬁfteen days, expansion cultures of sorted CD4þCD25þ
CD127lo/ or CD4þCD25 cells were terminated and FOXP3 expres-
sion analysed. Post-expansion, a big part of the sorted CD4þCD25
had become FOXP3þCD25þ but a higher percentage of the sorted
Tregs (CD4þCD25þCD127lo/ T-cells) expressed FOXP3 and also had
a higher FOXP3 expression, as shown in Fig. 5a, displaying an overlay
of the FOXP3þCD25þ expression after expansion of sorted
CD4þCD25þCD127lo/ cells and CD4þCD25 cells, from the same
individual. Fig. 5b shows the FOXP3þCD25þ expression after expan-
sion of sorted CD4þCD25 cells and Fig. 5c of sorted CD4þCD25þ
CD127lo/ cells. Cumulative data of the expansion of sorted CD4þ
CD25þCD127lo/ and CD4þCD25 conﬁrmed that a higher percen-
tage of sorted and expanded CD4þCD25þCD127lo/ was FOXP3
positive (po0.001, Fig. 5d). Moreover, expanded CD4þCD25þ
CD127lo/ had a higher mean ﬂuorescent intensity (MFI) of FOXP3,
both expressed as geometrical mean (po0.001, Fig. 5e) and mean
(po0.001, Fig. 5f), compared to expanded CD4þCD25 .
The percentage of FOXP3 expressing cells in the expanded
CD4þCD25þCD127lo/ cultures did not differ signiﬁcantly betweenT1D, healthy and high-risk individuals, even if T1D visually appeared
to be higher (Fig. 6a). Post-expansion, CD4þCD25þCD127lo/ from
T1D in contrast tended to display higher FOXP3 MFI, both expressed
as geometrical mean (p¼0.05, Fig. 6b) and mean (p¼0.05, Fig. 6c),
compared to healthy individuals.
Expansion of CD4þCD25 T-cells did not yield any signiﬁcant
differences in the percentage of FOXP3 expressing cells or in
FOXP3 MFI, neither expressed as geometrical mean nor mean
(data not shown).
3.5. Inﬂuence of age, nicotinamide treatment and
development of T1D
No differences, in regard to age distribution, were seen in
composition of the studied T-cell phenotypes in healthy or high-
risk individuals (data not shown). Neither was fold increase of
CD4þCD25þCD127lo/ T-cells correlated to age among the high-
risk, healthy or T1D individuals, nor in the total study population
as a group (data not shown).
The high-risk group was further split in regard to development
of T1D after inclusion in the study as well as split for treatment
with nicotinamide or placebo but showed no differences in T-cell
composition (data not shown).4. Discussion
During recent years, the interest for Tregs has increased, and
their role and function have been thoroughly scrutinized in a
plethora of studies. While their suppressive functions and impor-
tance in maintaining immune homoeostasis in experimental models
are generally acknowledged, their actual involvement in human
autoimmune disease is more disputed and reported ﬁndings are
non-unanimous. The development of T1D is associated with an
imbalance in the immune system connected to an autoimmune
p<0.001p<0.001p<0.001
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Fig. 6. The percentage of FOXP3 expressing cells in the expanded CD4þCD25þCD127lo/ Treg cultures (a) did not differ signiﬁcantly between T1D, healthy and high-risk
individuals. Post-expansion, CD4þCD25þCD127lo/ from T1D tended to display higher FOXP3 MFI, both expressed as (b) geometrical mean (p¼0.05) and (c) mean
(p¼0.05), compared to healthy individuals.
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have identiﬁed pieces of the immunological puzzle of T1D, seeking
to unravel the secret of the autoimmune riddle. However the origin,
the failing regulatory mechanism rendering subjects non-tolerant to
self remains elusive. Therefore, all pieces that can be added to this
puzzle will be important for the picture to appear.
Due to costly methods and logistics in sample collection,
isolated cells often need to be stored until further analysis can
be performed. Cryopreservation offers an opportunity to preserve
and store cells. In the research ﬁeld of Treg, however, one deals
with a quite small proportion of the total cell count and every
sample is highly valuable. Cryopreservation is a rather harsh
process to the handled cells that potentially could induce changes
in the marker expression, phenotype and function [25].
To be able to study Tregs, starting with small sample sizes due
to restricted sampling from T1D children, one goal of the studywas to gain a signiﬁcant expansion of Treg numbers. At times, the
only logical option when working with patient material is to
cryopreserve PBMCs. Cryopreservation may restrict the amount of
cells available, therefore, efﬁcient methods are of utmost
importance.
An important concern regarding ﬂow cytometry analysis of
cryopreserved cells is that the expression of surface- and intra-
cellular markers could be affected by the cryopreservation and
thereby alter the phenotypes of the studied cells. Hence, we
sought to establish the cryostability of Tregs. In our pre-study, the
Treg marker FOXP3 was analysed in the CD4þCD25hi population.
We were pleased to ﬁnd that the expression of FOXP3 was not
altered with regard to the percentage of expressing cells or MFI.
Neither did MFI of CD25 change markedly from sampling to post-
cryopreservation. Others have reported a somewhat diminished
suppressive function directly upon thawing but this will be
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cryopreservation, the suppressive effect was unaffected upon
thawing [26]. These results are positive, suggesting that Tregs
are stable for applications such as ﬂow cytometry and cell sorting
following cryopreservation and thawing. Importantly, others also
have shown that isolated Treg can survive cryopreservation [26].
While the so-called classic Treg gating strategy is based on the
concurrent expression of CD4 and the highest expression of CD25, as
only about 1–2% of the CD4þ cells, Liu et al. [11] demonstrated that
Tregs deﬁned by the concurrent expression CD4þCD25þCD127lo/ ,
as gated in Fig. 1, comprised a larger cell number but were as
suppressive. Further it has been shown that the exclusion of CD127hi
expressing cells, as done with this type of gating, allowed for
isolation of Tregs without contamination of memory effector cells
[24]. Beside the above mentioned ﬁndings, we found this gating
strategy for Tregs (Fig. 1) to be solid and it was therefore chosen
over the so-called classic gating strategy with CD4þ cells expressing
the highest levels of CD25. We were pleased that cryopreserved
PBMCs showed to be a suitable material for sorting and expanding
Tregs. Further, we were able to achieve powerful expansion of Tregs
from all individuals, independent of study group, even when starting
with as few as four thousand sorted Tregs. These results are
important, supporting the efﬁcaciousness of the method. A great
increase in Treg numbers despite a highly limited starting material
is also an important starting-point, should autologous Treg therapy
ever be the goal.
Although there was no statistical difference in fold increase of
Tregs between the study groups, Tregs of healthy study subjects
might be more prone to a higher fold increase than Tregs of T1D
subjects based on the display of higher fold expansion in half the
group in comparison to expansions seen from T1D and high-risk
individuals. A previous study asserted that fold expansion of
CD4þCD127lo/CD25þ T-cells was negatively correlated to age
[24]. However, we could not see any such negative correlation, or
a positive one, between ages and fold expansion in our study cohort.
Certainly it was not the youngest subjects in the healthy group that
expanded the most. Further, no difference in fold expansion of
CD4þCD25 T-cells between the groups was observed. This indi-
cates that despite the higher proportion of CD4þCD25 observed in
our cohort of T1D, there does not seem to be an altered proliferation
rate to engagement of CD3 and CD28.
Following expansion, almost all of the sorted CD4þCD25þ
CD127lo/ Tregs expressed FOXP3 as compared to expanded
CD4þCD25 responder cells, where a big but signiﬁcantly lower
percentage expressed FOXP3. Not only did a higher percentage of
sorted and expanded Tregs express FOXP3 compared to
CD4þCD25 T-cells post-expansion, but they also exhibited sig-
niﬁcantly higher intensity of FOXP3. This makes a strong case for the
use of sorted CD4þCD25þCD127lo/Tregs for expansion, since they
seem to generate cells with strong CD25þFOXP3þ expression.
Further, it could perhaps be speculated that the observed skewing
of the CD4þ T-cell composition towards a larger proportion of
CD4þCD25 cells in T1D children might render these individuals
more susceptible to certain threats. This could be speculated since
they hold a larger proportion of cells that upon engagement of CD3
and CD28 induce fewer FOXP3 expressing cells with lower FOXP3
intensity, in comparison to CD4þCD25þCD127lo/ cells.
Statistically, we did not see any difference between the study
groups, in the percentage of FOXP3 expressing cells in the
expanded Treg cultures. However, half of the observations for
T1D individuals were higher than all the other observations and
T1D also showed a tendency to higher FOXP3 intensity. No such
differences were seen for the sorted and expanded CD4þCD25
cells. Taken together, although T1D may be associated with a
smaller Treg proportion, they were able to achieve a great Treg
expansion and even acquired higher FOXP3 expression thanhealthy individuals. Considering the variation of the T-cell com-
position between the groups, one might hypothesize that the
Tregs of T1D are predominantly naı¨ve or resting Tregs which
could explain their good expansion potential and higher FOXP3
upregulation [27]. With this in mind, one could speculate that
T1D subjects possibly could beneﬁt from in vitro expansion and
re-introduction of the autologous Tregs to keep the immunologi-
cal process towards the pancreatic b-cells in check. It would have
been elegant and of great importance, to be able to show
functional data of the expanded CD4þCD25þCD127lo/ Tregs to
establish the efﬁcaciousness of the method and the possibility to
use the expanded cells as Tregs, in future applications. Unfortu-
nately, due to limited sample sizes, we were not able to show
such results.
Our study displayed a lower percentage of Tregs (CD4þCD25þ
CD127lo/) among the CD4þ cells in T1D children. This is in line
with studies describing reduced numbers of, or possibly func-
tionally weak, CD4þCD25hi Tregs in diseased individuals bearing
autoimmune disorders such as T1D, multiple sclerosis and auto-
immune polyglandular syndrome II [28–30]. This suggests that
Tregs could be part of the explanation of the failed ability to
maintain local self-tolerance during T1D development. However,
to make the picture more complex, there are also studies that fail
to present such differences for T1D patients [11,31]. One possible
explanation for the lack of consensus for Tregs in T1D, and other
disorders, could be the various ways of characterizing the cell
type and deﬁning the questions we ask on the impact of these
cells. In studies where Tregs are deﬁned as CD4þCD25hi, a certain
spectrum of cells will be included in the calculations, compared to
studies further adding FOXP3 and/or CD127 expression to the
deﬁnition. Given that different ways of describing the cell type are
used, part of the explanation for dissimilar ﬁndings could be as
simple as diverse deﬁnition of Tregs. Moreover, it is conceivable
that part of the explanation may be the diverse paths taken in the
quest to obtain the truth. While we are describing a lower fraction
of Tregs in T1D as a lower percentage of CD4þCD25þCD127lo/
cells in the CD4þ T-cell population, Liu et al. [11] addresses the
question as FOXP3 expression in the CD4þCD25þCD127lo/ ,
CD4þCD25CD127lo/ , CD4þCD25þCD127þ and CD4þCD25
CD127þ T-cell subsets.
In addition to a lower proportion of CD4þCD25þCD127lo/
cells in the total CD4þ population, we also found that the
relationship of CD4þCD25þCD127lo/ cells to CD4þCD25 cells
to be lower in T1D, conﬁrming the low Treg (CD4þCD25þ
CD127lo/) proportion seen in the total CD4þ population. This
skewed ratio, as compared with the healthy individuals, may be
explained by an elevated proportion of CD4þCD25 cells accom-
panying T1D and further strengthens the ﬁndings of a lower
proportion of CD4þCD25þCD127lo/ Tregs. The CD4þCD25
T-cells were recently described as a composition of responder
cells with a lower proliferation rate and slower IL-2 response to
in vitro stimulation, compared to already in vivo activated CD4þ
responder T-cells expressing low amounts of CD25 [32]. It was
recently shown that strong CD28 costimulation suppressed
induction of (i)Treg from CD4þCD25 T-cells [33]. At the same
time costimulation of CD28 is critical in the thymic development
of natural Tregs and their peripheral maintenance [34] and have
been suggested to be required in low levels for iTreg generation
[35]. Viral infections have been suggested in T1D development
and could perhaps explain the observations of skewed propor-
tions of CD4þ subsets, due to the high levels of CD28 costimula-
tion taking place during acute infection, causing expansion of
Teffs and hindering iTreg generation. One could also speculate
that if the suggested skewing towards higher proportions of
CD4þCD25 T-cells takes place before T1D development, this
could explain why a viral infection could induce such a powerful
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b-cells from an autoimmune attack.
Following these results, it came as no surprise that T1D subjects
exhibited a total CD4þCD25þ cell count lower than the one seen in
healthy individuals and furthermore a poorer percentage of the
T-cell subset of CD4þCD25þCD127þ cells. CD127 is down-regu-
lated on activated T-cells but is re-expressed in memory T-cells,
IL2R(CD25)loIL7R(CD127)þ , while Tregs remain CD127lo/ and a
dichotomy between them has been suggested [36]. The reduced
CD25þCD127þ population seen in our study is likely to contain
activated memory cells. Together these results are consistent and
suggestive of a shifted composition of the CD4þ T-cell subsets as a
part of the disease picture of T1D. One could contemplate whether
such alteration in the T-cell composition could be part of rendering
an individual incapable to mount a sufﬁcient suppressive and
protective response to an autoimmune attack. One explanation for
this might be that T1D has less activated (CD25þ) memory T-cells
and more resting (CD4þCD25) ones because they do not activate
so well. However, as the study was not designed to detect co-
expression of activation-, naı¨ve- or memory markers, this remains a
speculation. Previous ﬁndings suggested that aging is associated
with a shift in T-cell phenotype from a predominantly naı¨ve T-cell
subset (CD45RAþ) to a memory (CD45ROþ) T-cell phenotype [37].
However, in our study we could not derive any differences in the
T-cell composition to age, neither in the different study groups by
themselves or in the whole study population as a group.
We could not derive any correlations or differences in the
study material to age, nicotinamide treatment in high-risk indi-
viduals or whether high-risk individuals developed disease or not.
Thus, the results in our study cohort do not seem to be derived
from age related factors, but rather be connected to T1D. In line
with our study, Lindley et al. [38] did not ﬁnd a relationship
between age and CD25 expression, or between age and activation
markers on CD4þCD25þ .
In conclusion, based on the results from our study, cryopre-
served PBMC seems to be feasible for ﬂow cytometric analysis,
sorting and expansion of Tregs Marker expression was stable
through cryopreservation and thawing and an efﬁcient fold
expansion with preserved high FOXP3 expression was achieved.
Further, our study suggests that T1D is associated with a lower
percentage of Tregs, however, the ones present expanded well
and even acquired higher FOXP3 upregulation. Whereas we found
an altered composition of CD4þ subsets, biased towards a higher
CD4þCD25 ratio to CD4þCD25þCD127lo/ Tregs, the impor-
tance of the said alteration remains to be shown.Acknowledgement
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